Bristol Myers Squibb (BMY) R&D In Process (2021 - 2026)
Bristol Myers Squibb (BMY) reported R&D In Process of $94.0 million for Q1 2026, down 50.0% year-over-year from $188.0 million in Q1 2025, and down 93.25% on a QoQ basis from $1.4 billion in Q4 2025.
Bristol Myers Squibb (BMY) has 6 years of R&D In Process data on file, last reported at $94.0 million in Q1 2026.
- Quarterly R&D In Process fell 50.0% year-over-year to $94.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.6 billion (up 492.81% YoY) and the FY2025 annual result came in at $3.7 billion, down 72.18% from the prior year.
- R&D In Process slipped to $94.0 million in Q1 2026 per BMY's latest filing, from $1.4 billion in the prior quarter.
- Across five years, R&D In Process topped out at $12.9 billion in Q1 2024 and bottomed at $30.0 million in Q3 2022.
- The 5-year median for R&D In Process is $188.0 million (2025), against an average of $1.1 billion.
- The widest annual swing landed in 2024, when R&D In Process jumped 17165.33%; it then tumbled 98.55% in 2025.
- Tracing BMY's R&D In Process over 5 years: stood at $52.0 million in 2022, then surged by 1053.85% to $600.0 million in 2023, then plunged by 95.0% to $30.0 million in 2024, then jumped by 4543.33% to $1.4 billion in 2025, then plunged by 93.25% to $94.0 million in 2026.
- Per Business Quant, the three latest BMY R&D In Process figures stand at $94.0 million (Q1 2026), $1.4 billion (Q4 2025), and $633.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D In Process (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | 11.30 Bn |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 584.00 Mn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | - |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 744.00 Mn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | - |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 107.00 Mn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 137.00 Mn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 94.00 Mn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 94.00 Mn |
| Dec 31, 2025 | 1.39 Bn |
| Sep 30, 2025 | 633.00 Mn |
| Jun 30, 2025 | 1.51 Bn |
| Mar 31, 2025 | 188.00 Mn |
| Dec 31, 2024 | 30.00 Mn |
| Sep 30, 2024 | 262.00 Mn |
| Jun 30, 2024 | 132.00 Mn |
| Mar 31, 2024 | 12.95 Bn |
| Dec 31, 2023 | 600.00 Mn |
| Sep 30, 2023 | 80.00 Mn |
| Jun 30, 2023 | 158.00 Mn |
| Mar 31, 2023 | 75.00 Mn |
| Dec 31, 2022 | 52.00 Mn |
| Sep 30, 2022 | 30.00 Mn |
| Jun 30, 2022 | 400.00 Mn |
| Mar 31, 2022 | 333.00 Mn |
| Dec 31, 2021 | 89.00 Mn |
| Sep 30, 2021 | 271.00 Mn |
| Jun 30, 2021 | 793.00 Mn |
| Mar 31, 2021 | 6.00 Mn |